Curcumin may help slow growth of prostate tumour
Washington: Curcumin, an active component of the Indian curry spice turmeric, may help slow down the growth of tumour in castration-resistant prostate cancer patients on androgen deprivation therapy (ADT), a new study has found.
Karen Knudsen and colleagues from Jefferson’s Kimmel Cancer Centre, of Cancer Research observed in a pre-clinical study that curcumin suppresses two known nuclear receptor activators, p300 and CPB, or CREB1-binding protein, which have been shown to work against ADT.
ADT aims to inhibit the androgen receptor, an important male hormone in the development and progression of prostate cancer, in patients. But a major mechanism of therapeutic failure and progression to advanced disease is inappropriate reactivation of this receptor. Sophisticated tumour cells, with the help of p300 and CPB, sometimes bypass the therapy.
Thus, development of novel targets that act in concert with the therapy would be of benefit to patients with castration-resistant prostate cancer.
For the study, prostate cancer cells were subjected to hormone deprivation in the presence and absence of curcumin with “physiologically attainable” doses
Previous studies, which found similar results, included doses that were not realistic.
Curcumin augments the results of ADT, and reduced cell number compared to ADT alone, the researchers found. Moreover, the spice was found to be a potent inhibitor of both cell cycle and survival in prostate cancer cells.
To help support their findings, the researchers also investigated curcumin in mice, which were castrated to mimic ADT. They were randomized into two cohorts – curcumin and control. Tumour growth and mass were significantly reduced in the mice with curcumin, the researchers report.
These data demonstrate for the first time that curcumin not only hampers the transition of ADT-sensitive disease to castration-resistance, but also is also effective in blocking the growth of established castrate-resistant prostate tumours.
“This study sets the stage for further development of curcumin as a novel agent to target androgen receptor signalling,” Knudsen said.
“It also has implications beyond prostate cancer since p300 and CBP are important in other malignancies, like breast cancer. In tumours where these play an important function, curcumin may prove to be a promising therapeutic agent,” Knudesn added.
The study has been published in Cancer Research.